In addition, owing to the central role of estrogen-driven activation of CDK4/6 kinase in ER+ BC, multiple CDK4/6 kinase inhibitors, including palbociclib [55], ribociclib [56], and abemaciclib [57] have been developed for treating the advanced ER+ BC. This evidence concerns the gene ESR1 and breast cancer.